ecrin-mdr-crcClinical2013Patients with metastatic or unresectable locally advanced malignancies harboring specific genomic alterations regarding the biological crizotinib targets, and who are no more amenable to curative treatmentLiver carcinomaHematologic NeoplasmsRhabdomyosarcomaGlioblastomaColorectal cancerBreast cancerNeuroblastomaOvarian cancerThyroid cancerRenal cell carcinomaNon-small cell lung cancerAnaplastic large cell lymphoma T- and-cell typesInflammatory myofibroblastic tumourMetastatic CancerGastric cancerSolid TumorsCholangiocarcinomaHematologic CancersPatients With Metastatic Or Unresectable Locally Advanced Malignancies Harboring Specific Genomic Alterations Regarding The Biological Crizotinib Targets, And Who Are No More Amenable To Curative TreatmentHematologic NeoplasmsRhabdomyosarcomaGlioblastomaColorectal CancerInflammatory Myofibroblastic TumourNeuroblastomaBreast CancerOvarian CancerThyroid CancerGastric CancerNon-small Cell Lung CancerRenal Cell CarcinomaMetastatic CancerLiver CarcinomaAnaplastic Large Cell Lymphoma T- And-cell TypesSolid TumorsCholangiocarcinomaHematologic CancersInterventionalhttps://newmdr.ecrin.org/Study/2158683France8CrizotinibGenomic alterations.Biological crizotinib targets (ALK, MET, ROS1, RON, AXL).Metastatic or unresectable locally advanced malignancies.ECRIN MDRActive, not recruitingfalsePhase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1This is a biology driven, trans-tumoral, multicentric phase II trial assessing the efficacy and the safety of the targeted agent crizotinib as a monotherapy in 23 cohorts of patients with identified activating molecular alterations in the crizotinib target genes. A cohort is defined by a pathology and a crizotinib-target alteration (eg gastric cancer with MET amplification). For each cohort a two-stage design will be implemented. In the situation where expected accrual allows for a sufficient number of patients to be accrued, the alpha and beta errors will be fixed at 10%. However, in very rare diseases, such as inflammatory myofibroblastic tumor (IMT), neuroblastoma, glioblastoma, and rhabdomyosarcoma (RMS), it is anticipated that the target number may not be achievable in a reasonable timeframe; for these cohorts, the alpha and beta errors will be fixed at 15%. Consequently three different statistical designs will be a priori considered according to the expected response rate and incidence.2013-08-152158683NCT020349812013-000885-13